Intestinal microbiota and mucosa

The intestinal microbiota and mucosa constitute a dynamic biological system essential for metabolic homeostasis and immune regulation. The microbiota comprises a diverse community of bacteria, fungi, and viruses that facilitate nutrient metabolism and protect against pathogen colonization (NIH, 2023). Complementing this, the intestinal mucosa acts as a selective barrier, integrating physical structures like tight junctions with specialized immune cells to maintain systemic health (Nature Reviews Gastroenterology & Hepatology, 2020). Disruptions to this interface, characterized by altered microbial diversity or impaired barrier integrity, are central to the pathogenesis of inflammatory bowel disease, obesity, and colorectal cancer (Science, 2021). Pharmacological strategies targeting this system include the use of prebiotics, probiotics, and fecal microbiota transplants to restore microbial balance (Lancet, 2022). Additionally, biologics such as integrin inhibitors and TNF-alpha antagonists are employed to reduce mucosal inflammation and promote tissue healing (PubMed, 2023). Emerging research focuses on the gut-organ axes, exploring how microbial metabolites like short-chain fatty acids influence distant physiological processes in the liver, brain, and heart (Cell, 2019). This complex environment is increasingly viewed as a holistic therapeutic target for precision medicine in chronic inflammatory and metabolic diseases.

Other names

Gut microbiomeIntestinal barrierGut-mucosal interfaceGastrointestinal microbiotaIntestinal mucosal barrier

Therapeutic intervention involves the modulation of microbial community composition, restoration of epithelial tight junction integrity, and the regulation of mucosal immune signaling pathways to suppress chronic inflammation.